SpineJournal.gr | Spine News

New biologic bone graft product demonstrated superior fusion rates compared to current standard of care for complex fusion procedures of the lower spine in the pivotal clinical trial.

MINNEAPOLIS–(HSMN NewsFeed)–The U.S. Food and Drug Administration (FDA) Orthopaedic and Rehabilitation Devices Panel today voted 9 for and 4 against (1 abstention) on safety and 10 for and 3 against (1 abstention) on effectiveness, that data including results from a large, prospective randomized clinical trial demonstrated the safety and effectiveness of AMPLIFY™ rhBMP-2 Matrix for fusions of the lower spine in patients with degenerative disc disease. The benefits of this new bone graft option, which is specifically designed for single-level, posterolateral spinal fusion procedures, were also found by a majority of those voting to outweigh any risks associated with this product by a vote of 6 for and 5 against (3 abstention). More »

ALACHUA, Fla., Jul 22, 2010 (BUSINESS WIRE) — RTI Biologics Inc. (RTI) (RTIX 2.86, +0.06, +2.14%) , a leading processor of orthopedic and other biologic implants, announced today that Dean H. Bergy, 50, of Stryker Corporation has joined the company’s board of directors. He will be up for re-election in 2012. More »

WARSAW, Ind., July 22, 2010 /PRNewswire via COMTEX News Network/ –

Net Sales of $1.06 billion for the second quarter increased by 3.7% reported over the prior year period (an increase of 3.3% constant currency)
Diluted EPS for the second quarter were $0.82 reported, a decrease of 16.3% from the prior year period, and $1.09 adjusted, an increase of 9.0% over the prior year period
$1.5 billion stock repurchase program approved by Board of Directors More »

KALAMAZOO, Mich., July 20, 2010 /PRNewswire via COMTEX/ –
Stryker Corporation (NYSE: SYK) reported operating results for the quarter ended June 30, 2010 as follows:
Second Quarter Highlights
Net sales increased 6.9% on a constant currency basis (7.6% as reported) to $1,758 million
Orthopaedic Implants sales increased 1.4% on a constant currency basis (2.2% as reported)
MedSurg Equipment sales increased 15.9% on a constant currency basis (16.4% as reported)
Net earnings increased 9.5% from $291 million to $319 million
Diluted net earnings per share increased 9.6% from $0.73 to $0.80 More »